Drug Trial Radar · NCT05242471
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease
Last checked: Nov 20, 2026Latest source record: Nov 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
703
Actual
Start
Jul 22, 2022
Primary completion
May 23, 2025
Study completion Nov 5, 2029
Sponsor
- Lead sponsor
- Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
- Sponsor type
- Industry
- First posted
- Feb 16, 2022
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the efficacy of JNJ-78934804 at Week 48 compared to guselkumab and golimumab.
Conditions
- Crohn's Disease
Interventions
GuselkumabBiological
Guselkumab will be administered as subcutaneous injection.
GolimumabBiological
Golimumab will be administered as subcutaneous injection.
JNJ-78934804Biological
JNJ-78934804 will be administered subcutaneously as per defined regimen.
PlaceboDrug
Placebo will be administered as subcutaneous injection.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants with Clinical Remission at Week 48Time frame: Week 48
- Percentage of Participants with Endoscopic Response at Week 48Time frame: Week 48
Locations
456 sites in 36 countries. Site status is shown where the registry gives one.
University of Alabama Liver Center
Birmingham, Alabama
Del Sol Research Management, LLC
Tucson, Arizona
Moore Clinical Trials, LLC
Little Rock, Arkansas
Om Research LLC
Apple Valley, California
Valley Gastroenterology Medical Group
Arcadia, California
Southern California Research Center
Coronado, California
Desert Gastroenterology Associates
Lancaster, California
Cedars Sinai Medical Center
Los Angeles, California
UCLA
Los Angeles, California
Hoag Memorial Hospital
Newport Beach, California
UCI Irvine Medical Center
Orange, California
Medical Associates Research Group, Inc.
San Diego, California
University of California San Francisco
San Francisco, California
University of Colorado
Aurora, Colorado
Medical Research Center of Connecticut
Hamden, Connecticut
Yale University School Of Medicine
New Haven, Connecticut
MedStar Georgetown University Hospital
Washington D.C., District of Columbia
Pioneer Research Solutions Inc.
Coconut Creek, Florida
Homestead Associates in Research Inc
Homestead, Florida
Osceola Mental Health D/B/A Park Place Behavioral Health Care
Kissimmee, Florida
Florida Research Center Inc.
Lakewood Rch, Florida
University of Miami Hospital
Miami, Florida
Gastroenterology Group Of Naples
Naples, Florida
Omega Research Consultants
Orlando, Florida
Synergy Clinical Research
St. Petersburg, Florida
GCP Clinical Research
Tampa, Florida
Atlanta Gastroenterology Associates
Atlanta, Georgia
University of Mississippi Medical Center
Atlanta, Georgia
Gastroenterolgy Associates of Central GA
Macon, Georgia
Gastrointestinal Specialists of Georgia
Marietta, Georgia
Northwestern University
Chicago, Illinois
IU Health University Hospital
Indianapolis, Indiana
Gastroenterology of Southern Indiana
New Albany, Indiana
Cotton O'Neil Digestive Health Center
Topeka, Kansas
Ascension via Christi Research
Wichita, Kansas
Univ. of KS School of Med
Wichita, Kansas
Tri-State Gastroenterology Assoc
Crestview Hills, Kentucky
University of Kentucky
Lexington, Kentucky
Jewish Hospital
Louisville, Kentucky
Gastroenterology Clinic of Acadiana
Lafayette, Louisiana
Showing 40 of 456 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.